To include your compound in the COVID-19 Resource Center, submit it here.

Revance completes enrollment in Phase II trial of RT002 to treat plantar fasciitis

Revance Therapeutics Inc. (NASDAQ:RVNC) completed enrollment of 59 patients in a Phase II trial of

Read the full 159 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE